Exscientia inked a drug discovery collaboration with GlaxoSmithKline (NYSE:GSK) that could bring the Scotland-based company up to $37.5 million.
As a part of the deal, Exscientia plans to use its artificial-intelligence platform to discover small molecules for up to 10 disease-related targets, as chosen by GSK.
Get the full story at our sister site, Drug Delivery Business News.
The post GSK inks deal for AI-driven drug discovery appeared first on MassDevice.